Pharmacogenomics & Personalized Medicine

Scope & Guideline

Bridging science and patient care for personalized solutions.

Introduction

Welcome to the Pharmacogenomics & Personalized Medicine information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Pharmacogenomics & Personalized Medicine, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationPHARMACOGEN PERS MED / Pharmacogn. Pers. Med.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal 'Pharmacogenomics & Personalized Medicine' focuses on the integration of pharmacogenomics into clinical practice, emphasizing personalized medicine approaches to improve patient outcomes in various therapeutic areas. The following key aims and scopes summarize the core research focus of the journal.
  1. Pharmacogenomics and Drug Response:
    Research exploring the genetic factors influencing individual responses to medications, including polymorphisms in drug-metabolizing enzymes and transporters.
  2. Cancer Genomics and Personalized Treatment:
    Studies investigating the genetic underpinnings of cancer, including biomarkers for prognosis, treatment response, and the development of targeted therapies.
  3. Clinical Applications of Pharmacogenomics:
    Research highlighting the practical implementation of pharmacogenetic testing in clinical settings, aiming to tailor treatments based on genetic profiles.
  4. Genetic Epidemiology and Disease Susceptibility:
    Exploration of genetic variants associated with the risk and prognosis of various diseases, enhancing understanding of population-specific health issues.
  5. Innovative Therapeutic Strategies:
    Development and validation of novel therapeutic approaches based on genetic insights, including gene therapies and personalized medication regimens.
The journal has seen a notable increase in certain research themes, reflecting the evolving landscape of pharmacogenomics and personalized medicine. The following emerging themes have gained prominence in recent publications.
  1. Integration of Artificial Intelligence in Pharmacogenomics:
    Research utilizing AI and machine learning to analyze genetic data for predicting drug responses and optimizing treatment regimens is gaining traction.
  2. Immune Microenvironment and Cancer Therapy:
    Emerging studies focus on the relationship between genetic variations and the immune microenvironment, particularly in cancer therapies and immunotherapy responses.
  3. Long Non-Coding RNAs in Disease Mechanisms:
    Increasing research on the role of long non-coding RNAs in various diseases, their prognostic value, and their potential as therapeutic targets.
  4. Ethnic Diversity in Pharmacogenomics:
    A growing emphasis on studying pharmacogenomic variations across different ethnic groups, enhancing the understanding of population-specific drug responses.
  5. Personalized Nutrition and Pharmacogenomics:
    Research exploring the intersection of nutrition, genetics, and pharmacotherapy, highlighting how genetic factors can inform dietary recommendations alongside medication.

Declining or Waning

As the journal evolves, certain research themes appear to be receiving less emphasis in recent publications. The following points highlight areas that may be declining in focus as new trends emerge.
  1. General Pharmacology Studies:
    Traditional pharmacology studies that do not incorporate genetic factors or personalized approaches are becoming less prevalent, as the field shifts towards more tailored medicine.
  2. Case Reports without Genetic Insights:
    Case reports that do not focus on genetic variations or pharmacogenomic implications are less common, reflecting a shift towards genetic and molecular understanding in clinical cases.
  3. Broad Epidemiological Studies:
    While epidemiological studies remain important, those lacking a genetic component or personalized approach are increasingly overshadowed by studies integrating genomics into health outcomes.

Similar Journals

Oncology in Clinical Practice

Elevating Patient Outcomes Through Innovative Research
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

CURRENT TREATMENT OPTIONS IN ONCOLOGY

Transforming Research into Real-World Oncology Solutions
Publisher: SPRINGERISSN: 1527-2729Frequency: 12 issues/year

CURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.

CLINICAL THERAPEUTICS

Empowering clinicians with evidence-based therapeutic advancements.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Navigating the Complexities of Drug Action and Toxicity
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Unveiling the future of oncology through rigorous pharmacological research.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Expert Review of Clinical Pharmacology

Empowering clinicians with the latest in pharmacological advancements.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

ANTICANCER RESEARCH

Innovating Strategies for Cancer Combat
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

ANTI-CANCER DRUGS

Transforming Insights into Effective Cancer Solutions
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

INTERNATIONAL JOURNAL OF ONCOLOGY

Transforming discoveries into impactful cancer solutions.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Byulleten Sibirskoy Meditsiny

Exploring the Frontiers of Molecular Mechanisms and Therapies
Publisher: SIBERIAN STATE MEDICAL UNIVISSN: 1682-0363Frequency: 6 issues/year

Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.